Does not meet the criteria for a diet drug:

Generally, drugs aimed at weight loss are required to show a weight loss of at least 5%. Rybersus does not meet this standard.

Original indications are different :

Rybersus was developed as a treatment for type 2 diabetes, and weight loss is considered a secondary effect.

Insufficient safety data :

There is a lack of data on its safety for weight loss purposes.

Dosage restrictions:

There are restrictions on how you can take it, making it unsuitable for some lifestyles. You can only drink water within 30 minutes of waking up in the morning, which may limit your options if you value practicality in your daily life.

If that doesn't work:

It may not be effective for people who do not have diabetes.

Safety concerns in clinical trials:

In some clinical trials, deaths have been reported during the trial period. However, it is not clear whether these were a direct result of Rybersus, and these deaths should be interpreted with caution.

Availability:

As of June 2024, the 25 mg and 50 mg tablets of Rybersus are not sold or approved for sale in either the United States or Japan, making them difficult to obtain.

Possibility of inadequate effectiveness:

Rybersus should be taken as soon as you wake up in the morning, and you should only drink water for a certain period of time after that. If you do not use it properly, you may not achieve the intended purpose.

Reasons why we promote Rybersus in beauty clinics:

Cosmetic clinics tend to choose Rybelsus, which is easier to store, over GLP-1 receptor agonists such as Saxenda, which must be stored refrigerated.

For these reasons, it is believed that Rybelsus should not be used lightly as a diet drug.